{"id":43403,"date":"2025-10-15T13:03:05","date_gmt":"2025-10-15T05:03:05","guid":{"rendered":"https:\/\/flcube.com\/?p=43403"},"modified":"2025-10-15T13:03:05","modified_gmt":"2025-10-15T05:03:05","slug":"bio%e2%80%91thera-expands-canadian-partnership-with-intas-pharma-for-golimumab-biosimilar-bat2506","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43403","title":{"rendered":"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506"},"content":{"rendered":"\n<p><strong>Bio\u2011Thera Solutions (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA: 688177<\/a>)<\/strong> today announced the expansion of its collaboration with <strong>Intas Pharmaceuticals<\/strong> for the Canadian commercialization of <strong>BAT2506<\/strong>, a proposed golimumab biosimilar. The new exclusive commercialization and license agreement will give Intas\u2019 subsidiary <strong>Accord BioPharma<\/strong> the sole rights to market BAT2506 in Canada while Bio\u2011Thera retains control of development, manufacturing and supply.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-highlights\">Partnership Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td><strong>BAT2506<\/strong> \u2013 golimumab biosimilar (human IgG1 monoclonal antibody targeting TNF\u2011\u03b1)<\/td><\/tr><tr><td><strong>Original Reference<\/strong><\/td><td>Developed by J&amp;J as <strong>Simponi<\/strong><\/td><\/tr><tr><td><strong>Licensing Scope<\/strong><\/td><td>Exclusive commercialization in Canada (Accord BioPharma)<\/td><\/tr><tr><td><strong>Development Responsibility<\/strong><\/td><td>Bio\u2011Thera Solutions (manufacturing &amp; supply)<\/td><\/tr><tr><td><strong>Previous Collaboration<\/strong><\/td><td>USD\u202f164.5\u202fmillion partnership (Feb\u202f2025) granting Intas U.S. commercialization rights<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>Streamlines access to a high\u2011demand biologic for Canadian rheumatology patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Canadian Launch<\/strong> \u2013 The exclusive Canadian license positions BAT2506 for a rapid market entry, potentially filling a therapeutic gap for patients with rheumatoid arthritis and other TNF\u2011\u03b1 mediated conditions.<\/li>\n\n\n\n<li><strong>Revenue Upside<\/strong> \u2013 Bio\u2011Thera\u2019s retained supply chain control preserves margin while leveraging Intas\u2019 established commercial network.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong> \u2013 BAT2506 enters a crowded biosimilar market; the partnership with Intas enhances pricing and distribution leverage against incumbents.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-backgrounds\">Company Backgrounds<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bio\u2011Thera Solutions<\/strong> \u2013 A Shanghai\u2011listed biopharmaceutical company focused on developing and commercializing innovative biologics.<\/li>\n\n\n\n<li><strong>Intas Pharmaceuticals<\/strong> \u2013 A global specialty pharma company with a robust portfolio of biosimilars and a strong presence in the Canadian market through Accord BioPharma.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Bio\u2011Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43404,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[4347,289,1259,1055],"class_list":["post-43403","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-accord-biopharma","tag-bio-thera-solutions","tag-intas-pharmaceuticals","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio\u2011Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for the Canadian commercialization of BAT2506, a proposed golimumab biosimilar. The new exclusive commercialization and license agreement will give Intas\u2019 subsidiary Accord BioPharma the sole rights to market BAT2506 in Canada while Bio\u2011Thera retains control of development, manufacturing and supply.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43403\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506\" \/>\n<meta property=\"og:description\" content=\"Bio\u2011Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for the Canadian commercialization of BAT2506, a proposed golimumab biosimilar. The new exclusive commercialization and license agreement will give Intas\u2019 subsidiary Accord BioPharma the sole rights to market BAT2506 in Canada while Bio\u2011Thera retains control of development, manufacturing and supply.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43403\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T05:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506\",\"datePublished\":\"2025-10-15T05:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403\"},\"wordCount\":243,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1505.webp\",\"keywords\":[\"Accord BioPharma\",\"Bio-Thera Solutions\",\"Intas Pharmaceuticals\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43403#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43403\",\"name\":\"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1505.webp\",\"datePublished\":\"2025-10-15T05:03:05+00:00\",\"description\":\"Bio\u2011Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for the Canadian commercialization of BAT2506, a proposed golimumab biosimilar. The new exclusive commercialization and license agreement will give Intas\u2019 subsidiary Accord BioPharma the sole rights to market BAT2506 in Canada while Bio\u2011Thera retains control of development, manufacturing and supply.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43403\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1505.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43403#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506 - Insight, China&#039;s Pharmaceutical Industry","description":"Bio\u2011Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for the Canadian commercialization of BAT2506, a proposed golimumab biosimilar. The new exclusive commercialization and license agreement will give Intas\u2019 subsidiary Accord BioPharma the sole rights to market BAT2506 in Canada while Bio\u2011Thera retains control of development, manufacturing and supply.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43403","og_locale":"en_US","og_type":"article","og_title":"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506","og_description":"Bio\u2011Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for the Canadian commercialization of BAT2506, a proposed golimumab biosimilar. The new exclusive commercialization and license agreement will give Intas\u2019 subsidiary Accord BioPharma the sole rights to market BAT2506 in Canada while Bio\u2011Thera retains control of development, manufacturing and supply.","og_url":"https:\/\/flcube.com\/?p=43403","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-15T05:03:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43403#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43403"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506","datePublished":"2025-10-15T05:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43403"},"wordCount":243,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43403#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505.webp","keywords":["Accord BioPharma","Bio-Thera Solutions","Intas Pharmaceuticals","SHA: 688177"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43403#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43403","url":"https:\/\/flcube.com\/?p=43403","name":"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43403#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43403#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505.webp","datePublished":"2025-10-15T05:03:05+00:00","description":"Bio\u2011Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for the Canadian commercialization of BAT2506, a proposed golimumab biosimilar. The new exclusive commercialization and license agreement will give Intas\u2019 subsidiary Accord BioPharma the sole rights to market BAT2506 in Canada while Bio\u2011Thera retains control of development, manufacturing and supply.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43403#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43403"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43403#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505.webp","width":1080,"height":608,"caption":"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43403#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio\u2011Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43403"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43403\/revisions"}],"predecessor-version":[{"id":43405,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43403\/revisions\/43405"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43404"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}